Clinical trials: Conbercept
Diabetic Macular Edema, Pars Plana Vitrectomy
Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Diabetic Macular Edema
Diabetic macular edema (DME) is the main cause of vision loss in patients with diabetes. At present, anti-vascular endothelial growth factor (VEGF) intravitreal injection is the first-line therapy for DME, nevertheless, some…
- Conditions
- Diabetic Macular Edema, Pars Plana Vitrectomy, Conbercept
- Trial name
- NCT05728476
- Testing
- Vitrectomy combined with ILM peeling, Conbercept intravitreal injection
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Tianjin Medical University Eye Hospital
Polypoidal Choroidal Vasculopathy, Conbercept
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4.
- Trial name
- NCT05229237
- Testing
- Conbercept
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu